Abstract Insulin resistance (IR) underlines aging and agingassociated medical (diabetes, obesity, dyslipidemia, hypertension) and psychiatric (depression, cognitive decline) disorders. Molecular mechanisms of IR in genetically or metabolically predisposed individuals remain uncertain. Current review of the literature and our data presents the evidences that dysregulation of tryptophan (TRP)-kynurenine (KYN) and KYN-nicotinamide adenine dinucleotide (NAD) metabolic pathways is one of the mechanisms of IR. The first and ratelimiting step of TRP-KYN pathway is regulated by enzymes inducible by pro-inflammatory factors and/or stress hormones. The key enzymes of KYN-NAD pathway require pyridoxal-5-phosphate (P5P), an active form of vitamin B 6 , as a cofactor. Deficiency of P5P diverts KYN-NAD metabolism from production of NAD to the excessive formation of xanthurenic acid (XA). Human and experimental studies suggested that XA and some other KYN metabolites might impair production, release, and biological activity of insulin. We propose that one of the mechanisms of IR is inflammationand/or stress-induced upregulation of TRP-KYN metabolism in combination with P5P deficiency-induced diversion of KYN-NAD metabolism towards formation of XA and other KYN derivatives affecting insulin activity. Monitoring of KYN/P5P status and formation of XA might help to identify subjects at risk for IR. Pharmacological regulation of the TRP-KYN and KYN-NAD pathways and maintaining of adequate vitamin B 6 status might contribute to prevention and treatment of IR in conditions associated with inflammation/stress-induced excessive production of KYN and deficiency of vitamin B 6 , e.g., type 2 diabetes, obesity, cardiovascular diseases, aging, menopause, pregnancy, and hepatitis C virus infection.
Introduction
Insulin resistance (IR) underlines aging and aging-associated medical (diabetes, obesity, dyslipidemia, hypertension) and psychiatric (depression, cognitive decline) disorders [1, 2] . Molecular mechanisms of IR in genetically or metabolically predisposed individuals remain uncertain. Current review of the literature and our data presents the evidences that dysregulation of tryptophan (TRP)-kynurenine (KYN) and KYN-nicotinamide adenine dinucleotide (NAD) metabolic pathways is one of the mechanisms of IR. The first and rate-limiting step of TRP-KYN pathway is regulated by enzymes inducible by pro-inflammatory factors and/or stress hormones. The key enzymes of KYN-NAD pathway require pyridoxal-5-phosphate (P5P), an active form of vitamin B 6 , as a cofactor. Deficiency of P5P diverts KYN-NAD metabolism from production of NAD to the excessive formation of xanthurenic acid (XA). Human and experimental studies revealed that XA and some other KYN metabolites might impair production, release, and biological activity of insulin.
We propose that one of the mechanisms of IR is inflammation-and/or stress-induced upregulation of TRP-KYN metabolism in combination with P5P deficiencyinduced diversion of KYN-NAD metabolism towards formation of XA and other KYN derivatives affecting insulin activity.
Tryptophan-Kynurenine Metabolic Pathway
TRP is an essential (for humans) amino acid. About 5 % of nonprotein route of TRP metabolism is utilized for the formation of methoxyindoles: serotonin, N-acetylserotonin, and melatonin [3, 4] (Fig. 1) .
The major nonprotein route of TRP metabolism is formation of KYN, catalyzed by rate-limiting enzymes: indoleamine 2,3-dioxygenase (IDO) or TRP 2,3-dioxygenase (TDO) [4] . IDO is activated by pro-inflammatory mediators, e.g., interferon gamma (IFNG), tumor necrosis factor alpha, IL-1 beta, and lipopolysaccharide, while TDO is inducible by stress hormones, e.g., cortisol, estrogens, prolactin, and by a substrate, TRP [3] .
Kynurenine-Nicotinamide Adenine Dinucleotide Metabolic Pathway KYN is a substrate for two post-KYN metabolic pathways: (1) formation of kynurenic acid (KYNA), a precursor of quinaldic acid (QA), catalyzed by KYN aminotransferases (KAT) [5] , and (2) formation of 3-hydroxyKYN (3-HK) catalyzed by KYN 3-monooxygenase (KMO) [3, 4] .
The 3-HK is a substrate for two metabolic pathways: (1) formation of NAD, the first step of the 3-HK-NAD pathway, catalyzed by kynureninase, and (2) formation of xanthurenic acid (XA), catalyzed by 3-HK-transaminase [6] . XA is a precursor of 8-hydroxyquinaldic acid (8-HQ) [7] .
Pyridoxal 5′-Phosphate and KYN-NAD Metabolic Pathway P5P, an active form of vitamin B 6 , is a cofactor for >100 metabolic reactions, including key enzymes of post-KYN metabolism: KMO, KAT, and kynureninase, the latter enzyme is particularly sensitive to dietary vitamin B 6 restriction [8] . Downregulation of kynureninase, caused by P5P deficiency, shifts 3-HK metabolism from the formation of NAD to production of XA and KA [9] . P5P deficiency combined with upregulated TRP conversion to KYN leads to increased availability of 3-HK as a substrate for the formation of XA and 8-HQ and increased availability of KYN as a substrate for KYNA and QA in the cerebellum, corpus striatum, frontal cortex, and pons/medulla [10] , and in the blood [11] , urine [12] , and pancreatic islets [13, 14] .
Vitamin B 6 depletion resulted in a drastic increase, while vitamin B 6 supplementation normalized urinary 3-HK and XA after TRP load in cardiac [15] and obese [16] patients and rats [17] . Therefore, P5P deficiency combined with upregulation of TRP-KYN pathway might divert KYN-NAD metabolism towards the increased formation of XA at the expense of NAD production (Fig. 1) . The other consequence of P5P deficiency-induced downregulation of kynureninase is the decreased formation of NAD that leads to inhibition of synthesis and secretion of insulin and the death of pancreatic beta cells [18] . Considering that NAD inhibits TDO, decreased formation of NAD caused by P5P deficiency, might lead to further activation of TDO and increased production of KYN [19] .
Besides P5P deficiency, kynureninase might be inhibited by XA, thus sustaining the accumulation of 3-HK, KYNA, KYN, and XA at the expense of NAD production [20] . Additionally, XA might perpetuate P5P deficiency by inhibiting pyridoxal kinase, the enzyme catalyzing the formation of P5P from vitamin B 6 [21] .
It is noteworthy that vitamin B 6 dose dependently decreased insulin levels and improved insulin sensitivity in the experimental model of type 2 diabetes [22] .
Diabetogenic Effects of KYN Derivatives
Xanthurenic Acid Increased urine excretion of XA was reported in type 2 diabetes patients in comparison with that in healthy subjects [23] . Recent study found increased levels of XA precursors, KYN, and 3-HK in serum samples of diabetic retinopathy patients [24] . XA induced experimental diabetes in rats [25] .
The possible mechanisms mediating XA contribution to the development of diabetes might be the (1) formation of chelate complexes with insulin (XA-In); as antigens, XA-In complexes are indistinguishable from insulin but have 49 % lower activity than pure insulin [25] ; (2) formation of Zn ++ ions-insulin complexes in β cells that exert a toxic effect in isolated pancreatic islets [26, 27] ; (3) inhibition of insulin release from the rat pancreas [13] ; and (4) induction of pathological apoptosis of pancreatic beta cells through caspase 3-dependent mechanism [28, 29] .
Kynurenic Acid KYNA was found to be increased in the urine of nonhuman primate and mouse models of type 2 diabetes mellitus in a recent metabolomic study [30] and in patients with diabetic retinopathy [24] . KYNA (in micromolar concentrations) was detected in pancreatic juice of pigs [31] .
The possible mechanisms of diabetogenic effect of KYNA might be related to the KYNA's ability to block NMDA receptors. Thus, NMDA antagonist and pharmacological precursor of KYNA, 7-chlorokynurenic acid [4] , and NMDA antagonist, MK-801, negated the inhibition of glucose production induced by NMDA agonists injected into dorsal vagal complex in rodents [32] .
In addition, XA, KYNA, and their derivatives, QA and 8-HQ (in millimolar concentrations), inhibit proinsulin synthesis in isolated rat pancreatic islets [33] .
Recent study revealed elevated expression of IDO in serum samples of diabetic retinopathy patients [24] . In the same vein, surplus dietary TRP, the substrate for the formation of KYNA and XA, induced IR in pigs [34] .
Clinical Markers of Upregulation of TRP-KYN Pathway
Plasma (serum) ratio of KYN to TRP (KTR) is a generally accepted clinical marker of IDO activity [11] . Considering that both IDO and TDO regulate the rate of TRP conversion into KYN [35] , plasma concentrations of TRP and KYN might be affected by the activity of stress hormone-inducible TDO as well. However, KTR does reflect IDO activity in conditions associated with inflammation [2] .
Concurrently with induction of IDO, pro-inflammatory factors (e.g., IFNG, TNF-α, IL-1 beta) induce guanosine triphosphate cyclohydrolase I (GTPCH), a rate-limiting enzyme in the biosynthesis of BH4, the obligatory cofactor of NOS [36] . GTPCH catalyzes GTP conversion into 7,8-dihydroneopterin (BH2) [37] . Pro-inflammatory factor-induced activation of GTPCH results in the increased formation of neopterin, a stable, water-soluble derivative of BH2 [38] . Therefore, inflammation-induced elevation of neopterin production might be considered not simply a clinical marker of inflammation but an indirect marker of IDO activation as well [37] .
Blood neopterin levels correlate with KTR in healthy humans [39] and cardiovascular patients [11] . We found similar strong (r=0.68) and highly significant (p<0.0001) correlation between serum KTR ratio and neopterin in 80 hepatitis C virus (HCV) patients treated with interferon alpha (unpublished data). Diabetes Clinical and experimental data suggest the increased metabolism of TRP in diabetes, resulting most likely, from the upregulation of TRP-KYN pathway. Thus, impaired accumulation of TRP in the brain, concomitantly with a much faster disappearance of the administered TRP from the bloodstream, was observed in streptozotocin-induced diabetic rats after TRP load [36] . Similarly, post-loading levels of plasma TRP (but not of other large neutral amino acids) were lower in diabetic patients than in healthy controls [40] .
Recent studies reveal decreased plasma TRP concentrations and increased KYN and KTR in 21 hemodialysis patients with diabetes in comparison with 40 healthy controls patients. An increase in neopterin was correlated with KYN concentrations (r=0.393, p<0.01), suggesting that increased TRP degradation is a result of IDO activation [41] . In the same vein, neopterin but not C-reactive protein, an inflammation marker not related to IDO/GTPCH activation, is increased in diabetic patients in comparison with nondiabetic patients with critical limb ischemia [42] .
Decreased kynureninase activity was observed in the liver and kidney of alloxan-induced diabetic rabbits [43] . Additionally, XA was identified in prediabetes subjects [44] .
Neopterin correlated with IR, an early event in the pathogenesis of type 2 diabetes, in Caucasian population [11, 45, 46] . We observed a correlation between plasma neopterin concentrations and IR (homeostasis model assessment of insulin resistance (HOMA-IR), r=0.08, p<0.03) and P5P (r=−0.13, p=0.002) in 592 adult (45-75 years of age) participants of community dwellers in the Boston Puerto Rican Health Study. The strongest (r=0.15) and most significant (p<0.0002) correlation was recognized between HOMA-IR and neopterin/P5P ratio (a combined index of increased inflammation and P5P deficiency) [47] . Low plasma concentrations of P5P have been reported in conditions associated with increased fasting glucose and glycated hemoglobin [48] .
Obesity Obesity represents a major risk factor for the development of IR [49] and is considered as an independent cause of IR [50] . In most cases, IR exists because of the obesity and will disappear with weight loss [51] . Human obesity is characterized by chronic low-grade inflammation in white adipose tissue that releases many inflammatory mediators, including KYN [52, 53] . Serum KTR and IDO expression in the omental and subcutaneous adipose tissues and liver were higher in obese than in lean women [54] . KTR and neopterin and inflammatory markers, including C-reactive protein, were increased in morbid obese subjects [55] . However, only neopterin and KTR did not normalize after bariatric surgery and weight loss [55] . These studies suggested that IFNGinduced IDO and GTPCH activities have a unique role as the trait (VS state) inflammatory markers in obesity.
P5P deficiency was noted in 11 % of morbid obese individuals before laparoscopic sleeve gastrectomy [56] . Significantly lower P5P concentrations were reported in the morbidly obese Norwegian women and men [57] .
Depression The stress-induced TDO activation that shunts TRP metabolism from the formation of serotonin towards production of KYN in depression was originally suggested in 1969 [58] . Discovery of inflammation-inducible IDO added another mechanism of the upregulation of KYN formation from TRP in depression [59] . Association of depression with the increased production of cortisol [60] and inflammatory factors [61] is described elsewhere. Both IDO and TDO activation lead to the same major consequences: (1) deficiency of serotonin (and its metabolites, melatonin and Nacetylserotonin) contributing to insomnia, dysregulation of biological rhythms, and impaired neurogenesis observed in depression [62] [63] [64] and (2) upregulated formation of KYN and its neuroactive derivatives exerting anxiogenic, prooxidative, and cognitive impairment effects typical for depression [35, 65, 66] .
Increased plasma neopterin levels were reported in depressed patients, further supporting the notion of IDO activation in depression [67] . Low plasma concentrations of P5P have been reported in depression [68] . An increase in KTR and a deficiency in vitamin B 6 might explain the increased production of XA in depressed patients [69] . Although XA levels correlated with the severity of depression [69] , elevation of serum XA is not specific for depression, but rather, a marker of P5P deficiency [9, 11] . However, supplementation with P5P did not normalize elevated XA levels in depressed patients [69] .
The increased association between depression and IR (and diabetes) is generally acknowledged [70, 71] . Observation of a 65 % increased risk of development of (mostly type 2) diabetes in a prospective study of clinically depressed patients [72] supports the hypothesis that depression leads to diabetes [73] .
One of the mechanisms of the increased incidence of IR (and diabetes) in depressed subjects might be a combination of P5P deficiency with the upregulation of TRP-KYN and dysregulation of KYN-NAD metabolic pathways.
The role of IFNG-inducible IDO in the mechanisms of major depression might be further supported by the strong correlation between increased serum KTR and severity of depression, developed as a side effect of IFN-α treatment of HCV or melanoma patients [74] . We found that the presence of high producer (T) allele of IFNG (+874) T/A gene that encodes the production of pro-inflammatory cytokine, IFNG, increases the risk of development of depression during IFN-α treatment [75] . Serum neopterin concentrations were higher in HCV versus the non-HCV patient population and predicted resistance to IFN-α therapy [76] .
Hepatitis C Virus Incidence of IR among HCV patients is 50 % (fourfold) higher than that in non-HCV population [77] . HCV infection significantly lowered vitamin B 6 [78] . Antecedent HCV infection markedly increases the risk of developing diabetes in susceptible subjects, while even nondiabetic HCV patients have IR and specific defects in the insulin signaling pathway [79] . IFN-α treatment was associated with the additional risk of IR (and type 2 diabetes) in comparison with the group of non-viral chronic liver disease [80] or patients with chronic hepatitis B virus [81] . Serum KTR and neopterin concentrations were higher in HCV patients than in non-HCV population [82] . These data are in line with the current hypothesis that increased risk of IR in HCV patients depends on the combination of IFNG-induced upregulation of TRP-KYN metabolism with P5P deficiencyinduced dysregulation of KYN-NAD metabolic pathway.
Aging IR was originally suggested as a mechanism of aging by Dilman [83] [84] [85] [86] . IR is the key factor of aging metabolic syndrome [87] . Aging is associated with vitamin B 6 deficiency [88, 89] and increased plasma neopterin and KTR [46, 90] . Upregulation of TRP-KYN metabolism in aging might results both from activation of IDO due to ageassociated chronic inflammation [2] and/or TDO due to age-associated elevation of cortisol production [3, 84] .
XA accumulates in organs with aging and activates caspases 9 and 3, leading to apoptosis of pancreatic beta cells [28] .
Other Conditions Associated with Insulin Resistance
Cardiovascular Disease IR, increased KYN and neopterin production, and vitamin B 6 deficiency were reported in cardiovascular disease [11, 91, 92] .
Menopause Menopause is associated with IR [83, 84, 93, 94] . Production of IFNG, the most powerful activator of IDO, was increased in postmenopausal women [95] . Partial impairment in P5P-dependent kynureninase, suggesting a shift to increased production of diabetogenic XA (Fig. 1) , was observed in postmenopausal women [90] . This enzymatic activity could be partially restored by vitamin B 6 supplementation [96] .
Pregnancy and Gestations Upregulation of TRP-KYN metabolism [97, 98] and vitamin B 6 deficiency [8] might contribute to the development of gestational diabetes. Administration of vitamin B 6 improved oral glucose tolerance in gestational diabetes [99] .
Therapeutic Interventions Current hypothesis suggests that prevention and treatment of IR in conditions associated with chronic stress or chronic inflammation should include a combination of vitamin B 6 dietary supplementation and pharmacological modifications of TRP-KYN metabolism, aimed on downregulation of the formation of diabetogenic KYN derivatives. The latter may be achieved by administration of IDO/TDO inhibitors. The known IDO inhibitor, 1-methyl-L-TRY [100] , is not available for human use. There are two indirect (via downregulation of IFNG formation) IDO inhibitors available for human use: minocycline, an antibiotic with anti-inflammatory action [101, 102] , and Wellbutrin, an antidepressant [103] . It is noteworthy that Wellbutrin, contrary to tricyclic antidepressants, has a favorable metabolic profile [104] . Berberine, isoquinoline alkaloid isolated from Berberis aristata, a herb widely used in Indian and Chinese systems of medicine, inhibits IDO significantly stronger than 1-methyl-L-TRY [105] (Table 1) . Berberine improves IR in diabetic hamsters [106] and diabetic patients [107, 108] . It is noteworthy that both berberine and minocycline prolonged life span and improved health span in Drosophila model [109, 110] . Consistent with our hypothesis is the observation that vitamin B 6 supplementation dose dependently decreased insulin levels and improved IR in KK-A(y) mice, an animal model of obese, type 2 diabetes [111, 112] .
Conclusions
Review of the literature and our data suggests that inflammation and/or stress-induced upregulation of TRP-KYN metabolism, resulting in the excessive production of KYN, is one of the factors predisposing to IR. Deficiency of P5P, a cofactor of the key enzyme of KYN-NAD pathway, diverts the excessive amount of KYN from formation of NAD towards production of XA (and other) diabetogenic derivatives of KYN.
Monitoring of KYN/P5P status and formation of XA might help to identify subjects at risk for IR. Pharmacological regulation of the TRP-KYN and KYN-NAD pathways and maintaining of adequate vitamin B 6 status might contribute to the prevention and treatment of IR in conditions associated with inflammation/stress-induced excessive production of KYN and deficiency of vitamin B 6 , e.g., type 2 diabetes, obesity, cardiovascular diseases, aging, menopause, pregnancy, and hepatitis C virus infection.
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